AI Article Synopsis
- The study evaluated platelet activation and phagocytic activity in gastric cancer patients at different tumor stages.
- Results indicated that platelet counts and soluble platelet selectin levels increased with cancer progression, while phagocytic activity decreased, regardless of tumor stage.
- The findings suggest that the decline in phagocytic function may contribute to inflammation and cancer development.
Article Abstract
Aim: To assess the activation of platelets and their phagocytic activity in the course of gastric cancer.
Methods: Forty-three gastric cancer patients were recruited to the study. The patients were divided into 3 groups depending on tumor stage. Group E included 6 patients with early gastric cancer; group A 18 patients with locally advanced cancer; and group M-19 with metastatic cancer. The investigations were performed twice, prior to surgery and 12-14 d afterwards.
Results: The platelet count and the level of soluble platelet selectin (sP-selectin) were found to increase with the disease progression. The level of sP-selectin was lowest in early cancer and was observed to increase after surgery in all the study patients. Irrespective of tumor stage, a statistically significant decrease was noted in the percentage of phagocytizing platelets and in the phagocytic index in gastric cancer patients as compared to healthy subjects. Despite increased platelet count and stimulation of thrombocytopoiesis, the phagocytic functions of blood platelets were markedly impaired. Tumor development seems to impair metabolic processes.
Conclusion: A decreasing phagocytic activity can promote both inflammatory processes and cancer growth.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627834 | PMC |
| http://dx.doi.org/10.4291/wjgp.v4.i1.12 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IMPACT OF COVID-19 PANDEMIC ON THE SURGICAL TREATMENT OF GASTRIC CANCER: A 3-YEAR ANALYSIS.
Arq Bras Cir Dig
January 2025
Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Department of Gastroenterology - São Paulo (SP), Brazil.
Background: The COVID-19 pandemic has overloaded healthcare systems worldwide. Other diseases, such as neoplasms, including gastric cancer, remained prevalent and had their treatment compromised.
Aims: The aim of this study was to evaluate the impact of the COVID-19 pandemic on the treatment of gastric cancer and adherence to the recommended preoperative COVID-19 screening protocol.
[Gastric cancer cases in Brazil and waiting times for diagnosis and treatment].
Cien Saude Colet
January 2025
Departamento de Epidemiologia e Métodos Quantitativos, Escola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz. Rio de Janeiro RJ Brasil.
The aim is to describe the sociodemographic and clinical-epidemiological profile of hospital cases of gastric cancer and to analyze factors associated with the Time-to-Treatment in Brazil. Exploratory study of sociodemographic and clinical-epidemiological characteristics of cases of gastric cancer. Time-to-Treatment were continuously estimated and then categorized into ≤ 60/> 60 days to estimate prevalence.
View Article and Find Full Text PDFPreclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.
Eur J Nucl Med Mol Imaging
January 2025
Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI, 53705, USA.
Purpose: Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in various solid tumors and contributes to tumor progression, while its expression remains low in normal tissues. Trop2-targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen. Leveraging the enhanced specificity of ADCs, we conducted the first immunoPET imaging study of Trop2 expression in gastric cancer (GC) and triple-negative breast cancer (TNBC) models using Zr-labeled Trodelvy ([Zr]Zr-DFO-Trodelvy).
View Article and Find Full Text PDFBright and Specific Targeting of Metastatic Lymph Nodes in Orthotopic Mouse Models of Gastric Cancer with a Fluorescent Anti-CEA Antibody.
Ann Surg Oncol
January 2025
Department of Surgery, University of California San Diego, La Jolla, CA, USA.
Background: Gastric cancer poses a major diagnostic and therapeutic challenge. Improved visualization of tumor margins and lymph node metastases with tumor-specific fluorescent markers could improve outcomes.
Methods: To establish orthotopic models of gastric cancer, one million cells of the human gastric cancer cell line, MKN45, were suspended in 50 μl of equal parts PBS and Matrigel and injected into the nude mouse stomach with a 29-gauge needle.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!